Serum concentrations of immunoglobulins and of antibody isotypes in bone marrow transplant recipients treated with high doses of polyspecific immunoglobulin or with cytomegalovirus hyperimmune globulin
- PMID: 1661632
Serum concentrations of immunoglobulins and of antibody isotypes in bone marrow transplant recipients treated with high doses of polyspecific immunoglobulin or with cytomegalovirus hyperimmune globulin
Abstract
The kinetics of immunoglobulins (Ig) and antibodies were followed in 10 bone marrow transplant recipients who received either high doses (0.5 g/kg body weight) of polyspecific intravenous Ig (HD-IVIG) weekly or cytomegalovirus hyper-Ig (CMV-IVIG, 0.1 g/kg body weight) every 3 weeks. In the HD-IVIG group, the mean total IgG concentration more than tripled and similar significant increases were seen for IgG1 and IgG2. IgG antibodies to CMV showed a marked increase in the HD-IVIG and a less pronounced rise in the CMV-IVIG group. IgM antibodies to CMV were present initially or became detectable in five patients, unrelated to the IVIG preparation. HD-IVIG induced a significant increase of IgG antibodies to streptococcal group A carbohydrate (A-CHO) and to smooth strain lipopolysaccharides (LPS) but not of antibodies against lipid-A. When the Ig treatment was discontinued, levels of total IgG and of IgG antibody to CMV decreased with an apparent half-life of 30 days. Both IVIG preparations were well tolerated and had no negative feedback on total Ig and on specific antibody production or other antimicrobial defence mechanisms. In patient nos. 4 and 10 who developed severe graft-versus-host-disease, transient serum Ig peaks including several Ig isotypes appeared after day 14. In patient no. 10 this peak contained an IgG antibody to H. influenzae type b (Hib), and IgM antibodies to CMV, Hib, A-CHO and LPS. This study clearly shows that serum concentrations of Ig isotypes, subtypes and specific antibodies, depend on at least four factors: total amount and composition of Ig infused, consumption, catabolism and endogenous production.
Similar articles
-
[Serum immunoglobulin concentrations in patients following bone marrow transplantation and preventive administration of high-dose nonspecific or normal-dose CMV-specific immunoglobulin].Beitr Infusionsther. 1989;24:112-21. Beitr Infusionsther. 1989. PMID: 2481528 German.
-
Kinetics of cytomegalovirus IgG antibody following infusion of a hyperimmune globulin preparation in allogeneic marrow transplant recipients.Bone Marrow Transplant. 1989 May;4(3):267-72. Bone Marrow Transplant. 1989. PMID: 2543469
-
Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients.Haematologica. 1990 Mar-Apr;75(2):109-12. Haematologica. 1990. PMID: 2162799
-
What's new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus.J Dermatol. 2010 Mar;37(3):239-45. doi: 10.1111/j.1346-8138.2009.00796.x. J Dermatol. 2010. PMID: 20507387 Review.
-
[Intravenous gamma globulins (i.v.IG) in the treatment and prevention of virus infections].Przegl Epidemiol. 1992;46(3):231-6. Przegl Epidemiol. 1992. PMID: 1338350 Review. Polish.
Cited by
-
Immunoglobulin Replacement Therapy: Insights into Multiple Myeloma Management.Cancers (Basel). 2024 Sep 18;16(18):3190. doi: 10.3390/cancers16183190. Cancers (Basel). 2024. PMID: 39335161 Free PMC article. Review.
-
Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation.Eur J Clin Pharmacol. 1995;49(3):237-42. doi: 10.1007/BF00192385. Eur J Clin Pharmacol. 1995. PMID: 8666001
-
Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Clin Pharmacokinet. 2013 Feb;52(2):83-124. doi: 10.1007/s40262-012-0027-4. Clin Pharmacokinet. 2013. PMID: 23299465 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical